Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2020

01-12-2020 | NSCLC | Research article

A bioinformatics investigation into the pharmacological mechanisms of javanica oil emulsion injection in non-small cell lung cancer based on network pharmacology methodologies

Authors: Mengwei Ni, Xinkui Liu, Ziqi Meng, Shuyu Liu, Shanshan Jia, Yingying Liu, Wei Zhou, Jiarui Wu, Jingyuan Zhang, Siyu Guo, Jialin Li, Haojia Wang, Xiaomeng Zhang

Published in: BMC Complementary Medicine and Therapies | Issue 1/2020

Login to get access

Abstract

Background

Javanica oil emulsion injection (JOEI) is an effective therapeutic option for patients with non-small cell lung cancer (NSCLC), but its mechanisms have not been fully elucidated.

Methods

In this study, we utilized network pharmacology to systematically investigate the bioactive components and targets of JOEI, identify common targets in NSCLC, and understand and evaluate the underlying mechanism of JOEI in the treatment of NSCLC through expression level, correlation, enrichment, Cox, survival and molecular docking analyses. The results indicated that five compounds of JOEI interact with five pivotal targets (LDLR, FABP4, ABCB1, PTGS2, and SDC4) that might be strongly correlated with the JOEI-mediated treatment of NSCLC.

Results

The expression level analysis demonstrated that NSCLC tissues exhibit low expression of FABP4, ABCB1, LDLR and PTGS2 and high SDC4 expression. According to the correlation analysis, a decrease in FABP4 expression was strongly correlated with decreases in LDLR and ABCB1, and a decrease in LDLR was strongly correlated with decreased PTGS2 and increased in SDC4 expression. Cox and survival analyses showed that the survival rate of the high-risk group was significantly lower than that of the low-risk group (p = 0.00388). In the survival analysis, the area under the curve (AUC) showed that the pivotal gene model exhibited the best predictive capacity over 4 years (AUC = 0.613). Moreover, the molecular docking analysis indicated that LDLR, FABP4, ABCB1, PTGS2 and SDC4 exhibit good binding activity with the corresponding compounds.

Conclusion

In conclusion, this study predicted and verified that the mechanism of JOEI against NSCLC involves multiple targets and signaling pathways. Furthermore, this study provides candidate targets for the treatment of NSCLC, lays a good foundation for further experimental research and promotes the reasonable application of JOEI in clinical treatment.
Appendix
Available only for authorised users
Literature
1.
Tang X, Yang Y, Song X, Liu X, Wang X, Huang F, Li Y, Chen F, Wan H. SIX4 acts as a master regulator of oncogenes that promotes tumorigenesis in non-small-cell lung cancer cells. Biochem Biophys Res Commun. 2019;516(3):851–7.PubMedCrossRef
2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed
3.
Mortezaei Z, Tavallaei M, Hosseini SM. Considering smoking status, coexpression network analysis of non-small cell lung cancer at different cancer stages, exhibits important genes and pathways. J Cell Biochem. 2019;120(11):19172–85.PubMedCrossRef
4.
5.
Kogita A, Togashi Y, Hayashi H, Sogabe S, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition. Int J Oncol. 2014;45(4):1430–6.PubMedPubMedCentralCrossRef
6.
Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8(9):784–96.PubMedCrossRef
7.
Yao Y, Zhang X, Wang Z, Zheng C, Li P, Huang C, Tao W, Xiao W, Wang Y, Huang L, Yang L. Deciphering the combination principles of traditional Chinese medicine from a systems pharmacology perspective based on Ma-huang decoction. J Ethnopharmacol. 2013;150(2):619–38.PubMedCrossRef
8.
Chen R, He J, Tong X, Tang L, Liu M. The Hedyotis diffusa Willd. (Rubiaceae): A Review on Phytochemistry, Pharmacology, Quality Control and Pharmacokinetics. Molecules. 2016;21(6):710.PubMedCentralCrossRef
9.
Wang J, Ye HB, Dong Y. Effects of javanica oil emulsion injection combined with radiotherapy versus radiotherapy alone on the efficacy and safety in patients with esophageal cancer: a pooled analysis of 1269 cases. J BUON. 2017;22(4):985–95.PubMed
10.
Liu J, Li X, Liu J, Ma L, Li X, Fønnebø V. Traditional Chinese medicine in cancer care: a review of case reports published in Chinese literature. Forsch Komplementmed. 2011;18(5):257–63.PubMedCrossRef
11.
Chen Y, Lin Y, Li Y, Li C. Total flavonoids of Hedyotis diffusa Willd inhibit inflammatory responses in LPS-activated macrophages via suppression of the NF-κB and MAPK signaling pathways. Exp Ther Med. 2016;11(3):1116–22.PubMedCrossRef
12.
Ahmad R, Ali AM, Israf DA, Ismail NH, Shaari K, Lajis NH. Antioxidant, radical-scavenging, anti-inflammatory, cytotoxic and antibacterial activities of methanolic extracts of some Hedyotis species. Life Sci. 2005;76(17):1953–64.PubMedCrossRef
13.
Lin CC, Ng LT, Yang JJ, Hsu YF. Anti-inflammatory and hepatoprotective activity of peh-hue-juwa-chi-cao in male rats. Am J Chin Med. 2002;30(2–3):225–34.PubMedCrossRef
14.
Wang JC, Tian JH, Ge L, Gan YH, Yang KH. Which is the best Chinese herb injection based on the FOLFOX regimen for gastric cancer? A network meta- analysis of randomized controlled trials. Asian Pac J Cancer Prev. 2014;15(12):4795–800.PubMedCrossRef
15.
Wu JR, Liu SY, Zhu JL, Zhang D, Wang KH. Efficacy of Brucea javanica oil emulsion injection combined with the chemotherapy for treating gastric Cancer: a systematic review and Meta-analysis. Evid Based Complement Alternat Med. 2018. https://​doi.​org/​10.​1155/​2018/​6350782.
16.
17.
Ji ZQ, Huang XE, Wu XY, Liu J, Wang L, Tang JH. Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev. 2014;15(20):8603–5.PubMedCrossRef
18.
19.
Lu YY, Huang XE, Cao J, Xu X, Wu XY, Liu J, Xiang J, Xu L. Phase II study on Javanica oil emulsion injection (Yadanzi®) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev. 2013;14(8):4791–4.PubMedCrossRef
20.
Yang F, Yu XH, Qiao F, Cheng LH, Chen G, Long X, Wang XR, Li XL, Liang RC, Chen YZ. Formulation and characterization of Brucea javanica oil microemulsion for improving safety. Drug Dev Ind Pharm. 2014;40(2):266–77.PubMedCrossRef
21.
Wang Q, Wang M, He X, Gao T, Cao H, Dou W, Tian J. Meta-analysis on treatment of non-small cell lung cancer with brucea javanica oil emulsion in combination with platinum-contained first-line chemotherapy. Zhongguo Zhong Yao Za Zhi. 2012;37(13):2022–9.PubMed
22.
Liu L, Du B, Zhang H, Guo X, Zhou Z, Xiu A, Liu C, Su S, Ai H. A network pharmacology approach to explore the mechanisms of Erxian decoction in polycystic ovary syndrome. Chin Med. 2018;13(46):1–12.
23.
Wang S, Tong Y, Ng TB, Lao L, Lam JK, Zhang KY, Zhang ZJ, Sze SC. Network pharmacological identification of active compounds and potential actions of Erxian decoction in alleviating menopause-related symptoms. Chin Med. 2015;10(19):1–12.
24.
Wu L, Wang Y, Li Z, Zhang B, Cheng Y, Fan X. Identifying roles of “Jun-Chen-Zuo-Shi” component herbs of QiShenYiQi formula in treating acute myocardial ischemia by network pharmacology. Chin Med. 2014;9(24):1–9.
25.
Lee S. Systems biology - a pivotal research methodology for understanding the mechanisms of traditional medicine. Aust J Pharm. 2015;18(3):11–8.
26.
Zhang GB, Li QY, Chen QL, Su SB. Network pharmacology: a new approach for chinese herbal medicine research. Evid Based Complement Alternat Med. 2013;2013:621423.PubMedPubMedCentral
27.
Hao DC, Xiao PG. Network pharmacology: a Rosetta stone for traditional Chinese medicine. Drug Dev Res. 2014;75(5):299–312.CrossRef
28.
Li S. Exploring traditional chinese medicine by a novel therapeutic concept of network target. Chin J Integr Med. 2016;22(9):647–52.PubMedCrossRef
29.
Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Han L, He J, He S, Shoemaker BA, Wang J, Yu B, Zhang J, Bryant SH. PubChem substance and compound databases. Nucleic Acids Res. 2016;44(D1):D1202–13.PubMedCrossRef
30.
Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016;44(D1):D380–4.PubMedCrossRef
31.
Hong M, Li S, Tan HY, Cheung F, Wang N, Huang J, Feng Y. A network-based pharmacology study of the herb-induced liver injury potential of traditional Hepatoprotective Chinese herbal medicines. Molecules. 2017;22(4):632.PubMedCentralCrossRef
32.
Nickel J, Gohlke BO, Erehman J, Banerjee P, Rong WW, Goede A, Dunkel M, Preissner R. SuperPred: update on drug classification and target prediction. Nucleic Acids Res. 2014;42(W1):W26–31.PubMedPubMedCentralCrossRef
33.
Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res. 2014;42(W1):W32–8.PubMedPubMedCentralCrossRef
34.
Tang H, He S, Zhang X, Luo S, Zhang B, Duan X, Zhang Z, Wang W, Wang Y, Sun Y. A network pharmacology approach to uncover the pharmacological mechanism of XuanHuSuo powder on osteoarthritis. Evid Based Complement Alternat Med. 2016;2016:3246946.PubMedPubMedCentral
35.
Piñero J, Queralt-Rosinach N, Bravo À, Deu-Pons J, Bauer-Mehren A, Baron M, Sanz F, Furlong LI. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database (Oxford). 2015;2015:bav028.CrossRef
36.
37.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for rna-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.PubMedPubMedCentralCrossRef
38.
Yo YT, Shieh GS, Hsu KF, Wu CL, Shiau AL. Licorice and licochalcone-a induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. J Agric Food Chem. 2009;57(18):8266–73.PubMedCrossRef
39.
Bing Z, Cheng Z, Shi D, Liu X, Tian J, Yao X, Zhang J, Wang Y, Yang K. Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology. BMC Complement Altern Med. 2018;18(1):293.PubMedPubMedCentralCrossRef
40.
Sanga S, Vladimirova A, Goold RD, Klingler TM. Abstract 4870: GenePool: a cloud-based technology for rapidly data mining large-scale, patient-derived cancer genomic cohorts including the Cancer genome atlas. Cancer Res. 2015;75:4870.
41.
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–40.PubMedCrossRef
42.
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–8.PubMedCrossRef
43.
Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol. 2011;696:291–303.PubMedCrossRef
44.
Liu H, Zeng L, Yang K, Zhang G. A network pharmacology approach to explore the pharmacological mechanism of Xiaoyao powder on Anovulatory infertility. Evid Based Complement Alternat Med. 2016;2016:2960372.PubMedPubMedCentral
45.
Jeong H, Mason SP, Barabási AL, Oltvai ZN. Lethality and centrality in protein networks. Nature. 2001;411:41–2.PubMedCrossRef
46.
Newman MEJ. A measure of betweenness centrality based on random walks. Soc Networks. 2005;27(1):39–54.CrossRef
47.
48.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.PubMedPubMedCentralCrossRef
49.
Sun M, Song H, Wang S, Zhang C, Zheng L, Chen F, Shi D, Chen Y, Yang C, Xiang Z, Liu Q, Wei C, Xiong B. Integrated analysis identifies microRNA-195 as a suppressor of hippo-YAP pathway in colorectal cancer. J Hematol Oncol. 2017;10(1):79.PubMedPubMedCentralCrossRef
50.
Gene Ontology Consortium. Creating the gene ontology resource: design and implementation. Genome Res. 2001;11(8):1425–33.CrossRef
51.
Wixon J, Kell D. The Kyoto encyclopedia of genes and genomes—KEGG. Yeast. 2000;17(1):48–55.PubMed
52.
Walter W, Sánchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015;31(17):2912–4.PubMedCrossRef
53.
Kassambara A, Kosinski M, Biecek P. Survminer: drawing survival curves using ‘ggplot2’; 2016.
54.
Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–44.PubMedCrossRef
55.
Liu H, Wang L, Lv M, Pei R, Li P, Pei Z, Wang Y, Su W, Xie XQ. AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research. J Chem Inf Model. 2014;54(4):1050–60.PubMedPubMedCentralCrossRef
56.
57.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–91.PubMedPubMedCentralCrossRef
58.
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61.PubMedPubMedCentral
59.
60.
Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012;62(5):283–98.PubMedCrossRef
61.
Team NLSTR, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–91.CrossRef
62.
Tu SH, Ho CT, Liu MF, Huang CS, Chang HW, Chang CH, Wu CH, Ho YS. Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression. Food Chem. 2013;141(2):1553–61.PubMedCrossRef
63.
Xu W, Yang G, Xu Y, Zhang Q, Fu Q, Yu J, Yu M, Zhao W, Yang Z, Hu F, Han D, Wang X. The possibility of traditional chinese medicine as maintenance therapy for advanced nonsmall cell lung cancer. Evid Based Complement Alternat Med. 2014;2014:278917.PubMedPubMedCentral
64.
Zhang YX, Cheng XR, Zhou WX. Drug repositioning-the important field of network pharmacology. Chin J Pharm Toxicol. 2012;26(6):779–86.
65.
Wang J, Li XJ. Network pharmacology and drug discovery. Prog Physiol Sci. 2011;42(4):241–5.
66.
Liu X, Wu J, Zhang D, Wang K, Duan X, Meng Z, Zhang X. Network Pharmacology-Based Approach to Investigate the Mechanisms of Hedyotis diffusa Willd in the Treatment of Gastric Cancer. Evid Based Complement Alternat Med. 2018;2018:7802639.PubMedPubMedCentral
67.
Zhang S, Shan L, Li Q, Wang X, Li S, Zhang Y, Fu J, Liu X, Li H, Zhang W. Systematic analysis of the multiple bioactivities of green tea through a network pharmacology approach. Evid Based Complement Alternat Med. 2014;2014:512081.PubMedPubMedCentral
68.
Zhang Y, Mao X, Su J, Geng Y, Guo R, Tang S, Li J, Xiao X, Xu H, Yang H. A network pharmacology-based strategy deciphers the underlying molecular mechanisms of Qixuehe Capsule in the treatment of menstrual disorders. Chin Med. 2017;12(23):1–11.
69.
Li T, Baochen Z, Yue Z, Cheng W, Yali W, Zongxi S, Wantong Z, Yang L, Shouying D. Network pharmacology-based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer. Sci Rep. 2019;9(1):4533.PubMedPubMedCentralCrossRef
70.
Tang Z, Shen Q, Xie H, Zhou X, Li J, Feng J, Liu H, Wang W, Zhang S, Ni S. Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC). Oncotarget. 2016;7(29):46253–62.PubMedPubMedCentralCrossRef
71.
Chen H, Shien K, Suzawa K, Tsukuda K, Tomida S, Sato H, Torigoe H, Watanabe M, Namba K, Yamamoto H, Soh J, Asano H, Miyoshi S, Toyooka S. Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. Oncol Lett. 2017;14(4):4349–54.PubMedPubMedCentralCrossRef
72.
73.
Li Y, He LR, Gao Y, Zhou NN, Liu Y, Zhou XK, Liu JF, Guan XY, Ma NF, Xie D. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer. Cell Death Dis. 2019;10(2):99.PubMedPubMedCentralCrossRef
74.
Yang C, Gagnon C, Hou X, Hardy P. Low density lipoprotein receptor mediates anti-VEGF effect of lymphocyte T-derived microparticles in Lewis lung carcinoma cells. Cancer Biol Ther. 2010;10(5):448–56.PubMedPubMedCentralCrossRef
75.
Jiang GB, Fang HY, Tao DY, Chen XP, Cao FL. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner. Eur Rev Med Pharmacol Sci. 2019;23(9):3838–46.PubMed
76.
Ammu VVVRK, Garikapati KK, Krishnamurthy PT, Chintamaneni PK, Pindiprolu SKSS. Possible role of PPAR-γ and COX-2 receptor modulators in the treatment of non-small cell lung carcinoma. Med Hypotheses. 2019;124:98–100.CrossRef
77.
Dai P, Li J, Ma XP, Huang J, Meng JJ, Gong P. Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis. Onco Targets Ther. 2018;11:721–30.PubMedPubMedCentralCrossRef
78.
Zhou YY, Hu ZG, Zeng FJ, Han J. Clinical profile of Cyclooxygenase-2 inhibitors in treating non-small cell lung Cancer: a Meta-analysis of nine randomized clinical trials. PLoS One. 2016;11(3):e0151939.PubMedPubMedCentralCrossRef
79.
Che D, Zhang S, Jing Z, Shang L, Jin S, Liu F, Shen J, Li Y, Hu J, Meng Q, Yu Y. Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE2/β-catenin signalling pathway. Mol Immunol. 2017;90:197–210.PubMedCrossRef
80.
Butkiewicz D, Krześniak M, Drosik A, Giglok M, Gdowicz-Kłosok A, Kosarewicz A, Rusin M, Masłyk B, Gawkowska-Suwińska M, Suwiński R. The VEGFR2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer. Int J Cancer. 2015;137(10):2332–42.PubMedCrossRef
81.
Dajon M, Iribarren K, Petitprez F, Marmier S, Lupo A, Gillard M, Ouakrim H, Victor N, Vincenzo DB, Joubert PE, Kepp O, Kroemer G, Alifano M, Damotte D, Cremer I. Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. Oncoimmunology. 2018;8(1):e1505174.PubMedPubMedCentralCrossRef
82.
Erdem M, Erdem S, Sanli O, Sak H, Kilicaslan I, Sahin F, Telci D. Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma. Urol Oncol. 2014;32(1):25.e13–20.CrossRef
83.
Jr RR. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacol Res 2017; 121: 202–212.
84.
Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18(17):4570–9.PubMedPubMedCentralCrossRef
85.
Park S, Ahn BC, Lim SW, Sun JM, Kim HR, Hong MH, Lee SH, Ahn JS, Park K, Choi Y, Cho BC, Ahn MJ. Characteristics and outcome of ROS1-positive non-small cell lung Cancer patients in routine clinical practice. J Thorac Oncol. 2018;13(9):1373–82.PubMedCrossRef
86.
Fang IM, Yang CH, Yang CM, Chen MS. Linoleic acid-induced expression of inducible nitric oxide synthase and cyclooxygenase II via p42/44 mitogen-activated protein kinase and nuclear factor-kappaB pathway in retinal pigment epithelial cells. Exp Eye Res. 2007;85(5):667–77.PubMedCrossRef
87.
Shimizu K, Yukawa T, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy. World J Surg Oncol. 2015;13(21):1–7.
88.
Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, Arlinghaus R. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene. 2007;26(49):6989–96.PubMedPubMedCentralCrossRef
89.
Huang Q, Wang Q, Li D, Wei X, Jia Y, Zhang Z, Ai B, Cao X, Guo T, Liao Y. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):129.PubMedPubMedCentralCrossRef
90.
Pandya AD, Das MK, Sarkar A, Vilasagaram S, Basak S, Duttaroy AK. Tube formation in the first trimester placental trophoblast cells: differential effects of angiogenic growth factors and fatty acids. Cell Biol Int. 2016;40(6):652–61.PubMedCrossRef
91.
Latorre J, Moreno-Navarrete JM, Mercader JM, Sabater M, Rovira Ò, Gironès J, Ricart W, Fernández-Real JM, Ortega FJ. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD. Int J Obes. 2017;41(4):620–30.CrossRef
92.
Craig ZR, Wang W, Flaws JA. Endocrine-disrupting chemicals in ovarian function: effects on steroidogenesis, metabolism and nuclear receptor signaling. Reproduction. 2011;142(5):633–46.PubMedCrossRef
93.
Sasano H. Functional pathology of human ovarian steroidogenesis: Normal cycling ovary and steroid-producing neoplasms. Endocr Pathol. 1994;5(2):81–9.PubMedCrossRef
94.
Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52(4):585–9.PubMedPubMedCentralCrossRef
95.
Kuemmerle NB, Rysman E, Lombardo PS, Flanagan AJ, Lipe BC, Wells WA, Pettus JR, Froehlich HM, Memoli VA, Morganelli PM, Swinnen JV, Timmerman LA, Chaychi L, Fricano CJ, Eisenberg BL, Coleman WB, Kinlaw WB. Lipoprotein lipase links dietary fat to solid tumor cell proliferation. Mol Cancer Ther. 2011;10(3):427–36.PubMedPubMedCentralCrossRef
96.
Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010;140(1):49–61.PubMedPubMedCentralCrossRef
97.
Metadata
Title
A bioinformatics investigation into the pharmacological mechanisms of javanica oil emulsion injection in non-small cell lung cancer based on network pharmacology methodologies
Authors
Mengwei Ni
Xinkui Liu
Ziqi Meng
Shuyu Liu
Shanshan Jia
Yingying Liu
Wei Zhou
Jiarui Wu
Jingyuan Zhang
Siyu Guo
Jialin Li
Haojia Wang
Xiaomeng Zhang
Publication date
01-12-2020
Publisher
BioMed Central
Keywords
NSCLC
NSCLC
Published in
BMC Complementary Medicine and Therapies / Issue 1/2020
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-020-02939-y

Other articles of this Issue 1/2020

BMC Complementary Medicine and Therapies 1/2020 Go to the issue

Research article

Insights into the mechanism of Arnebia euchroma on leukemia via network pharmacology approach

Research article

The effects of six months Persicaria minor extract supplement among older adults with mild cognitive impairment: a double-blinded, randomized, and placebo-controlled trial

Research article

Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression

Review

Anti-trichomonad activities of different compounds from foods, marine products, and medicinal plants: a review

Research article

A network pharmacology study on the Tripteryguim wilfordii Hook for treatment of Crohn’s disease

Research article

Genistein contributes to cell cycle progression and regulates oxidative stress in primary culture of osteoblasts along with osteoclasts attenuation